Biliary Tract Cancers Pipeline Appears Robust With 80+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight

Advertisements

DelveInsight’s, “Biliary Tract Cancers Pipeline Insight, 2023,” report provides comprehensive insights about 80+ companies and 80+ pipeline drugs in Biliary Tract Cancers pipeline landscape. It covers the pipeline drug profiles, including Biliary Tract Cancers clinical trials and nonclinical stage products. It also covers the Biliary Tract Cancers pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

 

In the Biliary Tract Cancers pipeline report, detailed description of the drug is given which includes mechanism of action of the drug, Biliary Tract Cancers clinical trials studies, Biliary Tract Cancers NDA approvals (if any), and product development activities comprising the technology, biliary tract cancer collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

 

Key takeaways from the Biliary Tract Cancers Pipeline Report

 

DelveInsight’s Biliary Tract Cancers Pipeline report depicts a robust space with 80+ active players working to develop 80+ pipeline therapies for Biliary Tract Cancers.

 

The leading Biliary Tract Cancers Companies includes Eli Lilly and Company, Merck Sharp & Dohme Corp., InnoPharmax Inc., Shanghai Miracogen Inc., AstraZeneca, CSPC ZhongQi Pharmaceutical Technology Co., Ltd., Lee’s Pharmaceutical Limited, RemeGen Co., Ltd., Zymeworks Inc., BeiGene, Ltd., Hoffmann-La Roch, Eisai Co., Ltd., Chia Tai Tianqing Pharmaceutical Group, Adherex Technologies, Inc., and others.

 

Promising Biliary Tract Cancers pipeline therapies includes M7824, Atezolizumab, Bevacizumab, Lenvatinib, ZW25 (Zanidatamab), Gemcitabine, Cisplatin, S-1/Gemcitabine, Ramucirumab, Nivolumab, TH-302 monotherapy, and others.

 

The Biliary Tract Cancers companies and academics are working to assess challenges and seek opportunities that could influence biliary tract cancer R&D. The Biliary Tract Cancers pipeline therapies under development are focused on novel approaches to treat/improve Asthma.

 

 

To explore more information on the latest breakthroughs in the Biliary Tract Cancers Pipeline treatment landscape of the report, click here @ Biliary Tract Cancers Pipeline Outlook

 

Recent Developmental Activities in the Biliary Tract Cancers Treatment Landscape

 

In January 2022, orphan drug designation (ODD) was received for Silmitasertib for the treatment of biliary tract cancer, a rare, malignant disease for which there are no effective therapies.

 

In 2022, Genome and Company and Merck (MSD) have signed a clinical trial collaboration and supply agreement to analyse GEN-001 plus Keytruda (pembrolizumab) in a Phase II clinical trial to treat biliary tract cancer.

 

In November 2020, orphan designation was granted by the European Commission for Zanidatamab (also known as ZW25) for the treatment of gastric cancer.

 

Biliary Tract Cancer Overview

Biliary tract cancer is a cancer that forms in the cells of the bile ducts, gallbladder or ampulla of Vater. Cancer of the bile ducts is called cholangiocarcinoma and is classified depending on which part of the bile duct the cancer develops into intrahepatic (affects bile ducts within the liver), hilar (occurs at the junction of the left and right hepatic ducts) and extrahepatic (affects the common bile duct outside the liver) sharing different genetic, risk factors and clinical presentation. Diagnosis of biliary tract cancer is done by ultrasound, computerized tomography (CT) scans and magnetic resonance imaging (MRI) combined with magnetic resonance cholangiopancreatography (MRCP). Surgical procedure to remove the tumor is the only curative way but disease recurrence is frequent. Treatment with chemotherapy and radiotherapy works as adjuvant therapy. New ongoing studies like targeted therapy and immunotherapy mainly in the adjuvant and neoadjuvant setting along with molecular research will hopefully help to improve survival and quality of life of this disease.

 

Request a sample and discover the recent advances in Biliary Tract Cancer Ongoing Clinical Trial Analysis and Medications, click here @ Biliary Tract Cancer Treatment Landscape

 

Biliary tract cancer: Emerging Drugs  

Durvalumab: AstraZeneca

Durvalumab is an anticancer antibody that works to promote the anti-tumor responses mediated by immune cells. It is a human immunoglobulin G1 kappa (IgG1κ) monoclonal antibody that blocks the interaction of programmed cell death ligand 1 (PD-L1) with the PD-1 (CD279). A randomized, double-blind placebo controlled, multi-regional phase III are being conducted to evaluate the effect of Durvalumab in Combination with Gemcitabine Plus Cisplatin Versus Placebo in Combination with Gemcitabine Plus Cisplatin for Patients With First-Line Advanced Biliary Tract Cancers. This study is expected to get completed by July 2022. 

 

MRG 002: Miracogen

MRG 002, is an antibody-drug conjugate (ADC) composed of a humanized immunoglobulin G1 (IgG1) monoclonal antibody directed against the tumor-associated antigen (TAA) human epidermal growth factor receptor 2 conjugated to the microtubule-disrupting cytotoxic agent monomethyl auristatin E (MMAE), with potential antineoplastic activity. An open-label, single-arm, multi-center, phase II Clinical Study of MRG002 are conducted by Miracogen for the treatment of patients with HER2-positive unresectable, locally advanced or metastatic biliary tract cancer. MRG002 is administrated by an IV infusion of 2.6 mg/kg on Day 1 of every 3 weeks (21-day cycle). 

 

Zanidatamab: Zymeworks

Zanidatamab, is a HER2-targeted bispecific antibody developed by Zymeworks. Zanidatamab binds to two distinct sites on HER2, a protein expressed on many types of cancer cells. This results in multiple mechanisms of action, including dual HER2 signal blockade, increased antibody binding, receptor clustering, and removal of HER2 from the cell surface, and potent effector function. Zanidatamab have received Orphan Drug designation for the treatment of biliary tract and gastric cancers in the United States. Zymeworks is currently conducting phase II study of Zanidatamab (ZW25) plus first-line combination chemotherapy in HER2-Expressing Gastrointestinal (GI) Cancers, Including Gastroesophageal Adenocarcinoma (GEA), Biliary Tract Cancer (BTC), and Colorectal Cancer (CRC). 

AZD5305: Astra Zeneca

AZD5305 is a PARP-1 selective inhibitor. In cancer treatment, PARP inhibitors stop the PARP from doing its repair work in cancer cells and the cell dies. A phase I/IIa, open-label, multicenter trials are under progress to assess the safety, tolerability, pharmacokinetics, pharmacodynamics and preliminary efficacy of ascending doses of AZD5305 as monotherapy and in combination with Anti-cancer agents in patients with advanced solid malignancies.

 

Ramucirumab: Eli Lilly and Company 

Ramucirumab, an immunotherapy drug, is a monoclonal antibody that works by targeting and restricting a protein that stimulates blood vessel growth within tumors. Vascular endothelial growth factor receptor 2 (VEGFR2) antagonist that specifically binds VEGF receptor 2 and blocks binding of VEGFR ligands, VEGF-A, VEGF-C, and VEGF-D. Ramucirumab inhibits ligand-stimulated activation of VEGF2, thereby inhibiting ligand-induced proliferation, and migration of human endothelial cells. Eli Lily and Company is conducting Phase I clinical trials to study Ramucirumab plus Pembrolizumab in patients with locally advanced and unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma, non-small cell lung cancer, transitional cell carcinoma of the urothelium, or biliary tract cancer.  

 

Biliary Tract Cancers Pipeline Therapeutics Assessment

There are approx. 80+ key companies which are developing the therapies for Asthma. The companies which have their biliary tract cancer drug candidates in the most advanced stage, i.e. phase III include, AstraZeneca.

 

For further information, refer to the detailed Biliary Tract Cancers Unmet Needs, Biliary Tract Cancers Market Drivers, and Market Barriers, click here for Biliary Tract Cancers Ongoing Clinical Trial Analysis

 

Scope of the Biliary Tract Cancers Pipeline Report

 

Coverage- Global

 

Biliary Tract Cancers Companies- includes Eli Lilly and Company, Merck Sharp & Dohme Corp., InnoPharmax Inc., Shanghai Miracogen Inc., AstraZeneca, CSPC ZhongQi Pharmaceutical Technology Co., Ltd., Lee’s Pharmaceutical Limited, RemeGen Co., Ltd., Zymeworks Inc., BeiGene, Ltd., Hoffmann-La Roch, Eisai Co., Ltd., Chia Tai Tianqing Pharmaceutical Group, Adherex Technologies, Inc., and others.

 

Biliary Tract Cancers pipeline therapies- M7824, Atezolizumab, Bevacizumab, Lenvatinib, ZW25 (Zanidatamab), Gemcitabine, Cisplatin, S-1/Gemcitabine, Ramucirumab, Nivolumab, TH-302 monotherapy, and others

 

Biliary Tract Cancers Pipeline Segmentation: Phases, Product Type, Molecule Type, Mechanism of Action, Route of Administration

 

 

Dive deep into rich insights for drugs for Biliary Tract Cancers Market Drivers and Biliary Tract Cancers Market Barriers, click here @ Biliary Tract Cancers Unmet Needs and Analyst Views

 

Table of Content

Introduction
Executive Summary
Biliary tract cancer Overview
Pipeline Therapeutics
Biliary tract cancer– DelveInsight’s Analytical Perspective
Late Stage Products (Phase III)
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
MRG 002: Miracogen
Drug profiles in the detailed report…..
Early Stage Products (Phase I/II)
AZD5305: Astra Zeneca
Drug profiles in the detailed report…..
Early Stage Products (Phase I)
Ramucirumab: Eli Lilly and Company
Drug profiles in the detailed report…..
Inactive Products
Biliary tract cancer Key Companies
Biliary tract cancer Key Products
Asthma- Unmet Needs
Asthma- Market Drivers and Barriers
Asthma- Future Perspectives and Conclusion
Biliary tract cancer Analyst Views
Biliary tract cancer Key Companies
Appendix

 

Got Queries? Find out the related information on Biliary tract cancer Mergers and acquisitions, Biliary tract cancer Licensing Activities @ Biliary tract cancer Emerging Drugs, and Recent Trends

 

 

About Us

DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/consulting/due-diligence-services

Daily Digest Signup

Daily business and market business news, business management tips, market research insights, and more.

Advertisements

Smart public opinion research for everyone.

Generated by Feedzy
%d bloggers like this: